YM155

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer

Conditions

Cancer

Trial Timeline

Nov 1, 2009 → Mar 1, 2010

NCT ID

NCT01023386

About YM155

YM155 is a phase 1 stage product being developed by Astellas Pharma for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01023386. Target conditions include Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00257478	Phase 2	Completed	—	Mar 1, 2007	Prostate Cancer
NCT01023386	Phase 1	Completed	Nov 1, 2009	Mar 1, 2010	Cancer
NCT00498914	Phase 2	Terminated	Jun 1, 2007	Apr 1, 2009	Lymphoma, Large-Cell, Diffuse
NCT00328588	Phase 2	Completed	Dec 1, 2006	Mar 1, 2007	Lung Cancer
NCT00818480	Phase 2	Completed	Feb 1, 2006	Aug 1, 2012	Prostate Cancer
NCT00281541	Phase 2	Completed	Nov 1, 2005	Jun 1, 2007	Melanoma

Competing Products

20 competing products in Cancer

See all competitors

Product	Company	Stage	Hype Score
mFOLFOX regimen + Mitazalimab	Alligator Bioscience AB	Phase 2/3	35
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
mRNA-2416	Moderna	Phase 2	0
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
E7389	Eisai	Phase 1	29
Veliparib	AbbVie	Phase 2	27
AK-105	Akeso	Phase 1	29
XL820	Exelixis	Phase 1	26
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
pemetrexed	Eli Lilly	Phase 2	27
LY3300054 + Prexasertib	Eli Lilly	Phase 1	29
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35